Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-07-16), Vita Life Sciences's 6-1 Month Momentum % is -12.77%.
The industry rank for Vita Life Sciences's 6-1 Month Momentum % or its related term are showing as below:
ASX:VLS's 6-1 Month Momentum % is ranked better than 55.77% of 1031
companies
in the Drug Manufacturers industry
Industry Median: -11.94
vs ASX:VLS: -12.77
Vita Life Sciences (ASX:VLS) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vita Life Sciences 6-1 Month Momentum % Related Terms
ASX:VLS vs ZTS, UTHR: 6-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences 6-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's 6-1 Month Momentum % falls into.
Vita Life Sciences (ASX:VLS) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a 6-1 Month Momentum % of -12.77% as of Jul. 16, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vita Life Sciences and its competitors. According to the industry distribution chart, Vita Life Sciences ranks #456 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 44.2%.
Is Vita Life Sciences' 6-1 Month Momentum % too high?
Vita Life Sciences' current 6-1 Month Momentum % is -12.77%. Based on the distribution chart, Vita Life Sciences ranks #456 out of 1031 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' 6-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #456 out of 1031 companies for 6-1 Month Momentum %. This puts Vita Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Drug Manufacturers company?
A good 6-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vita Life Sciences and its competitors. Vita Life Sciences's current 6-1 Month Momentum % is -12.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.49, compared to a current price of A$2.48 — trading 0.4% below its estimated fair value. The current 6-1 Month Momentum % is -12.77%. Vita Life Sciences' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current 6-1 Month Momentum % is -12.77% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.48 is trading 0.4% below its estimated GF Value™ of A$2.49.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
6-1 Month Momentum %: -12.77%
GF Value™: A$2.49 vs. price of A$2.48 (0.4% below fair value)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
78GF Score
Get the complete analysis for ASX:VLS
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
